Cargando…

P1120: NOVEL TARGETED AGENTS IN COMBINATION WITH R-ICE (R-ICE-X) BASED ON GENOTYPING IN RELAPSED/REFRACTORY DLBCL.

Detalles Bibliográficos
Autores principales:	Yige, Shen, Cao, Yi-Wen, Cheng, Shu, Xu, Peng-Peng, Wang, LI, Zhao, Wei-LI
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431152/ http://dx.doi.org/10.1097/01.HS9.0000971376.08513.7b

Ejemplares similares

P1168: DURABLE REMISSION AFTER SEQUENTIAL CD19/20 CAR T-CELL “CAKE-ICING” THERAPY OCCURRED IN REFRACTORY/RELAPSED DLBCL
por: Zheng, Peihao, et al.
Publicado: (2023)

P1144: PHASE 2 WAVELINE-004 STUDY: ZILOVERTAMAB VEDOTIN (MK-2140) IN RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
por: Ozcan, Muhit, et al.
Publicado: (2023)

P1174: PI3K INHIBITOR LINPERLISIB COMBINED WITH GEMCITABINE AND OXALIPATIN (GEMOX) IN RELAPSED AND/OR REFRACTORY DLBCL: ANALYSIS BASED ON TUMOR BIOLOGY
por: Zhi-Ming, LI, et al.
Publicado: (2023)

P1210: IMMUNE CORRELATES OF RESPONSE TO GLOFITAMAB: BIOMARKER FINDINGS FROM A PIVOTAL PHASE II EXPANSION STUDY IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
por: Piccione, E. C., et al.
Publicado: (2022)

P1126: PHASE 1B/2A STUDY OF AZD4573 (CDK9I) AND ACALABRUTINIB IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL)
por: Strati, Paolo, et al.
Publicado: (2023)

Comparative ICE Genomics: Insights into the Evolution of the SXT/R391 Family of ICEs
por: Wozniak, Rachel A. F., et al.
Publicado: (2009)

Extranucleolar CYCLON Staining Pattern Is Strongly Associated to Relapse/Refractory Disease in R-CHOP–treated DLBCL
por: Bouroumeau, Antonin, et al.
Publicado: (2021)

P1695: REAL-WORLD SURVIVAL, HEALTHCARE RESOURCE UTILIZATION, AND COSTS AMONG U.S. ELDERLY PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TREATED WITH R-GEMOX IN THE RELAPSED/REFRACTORY SETTING
por: Garg, Mahek, et al.
Publicado: (2023)

P1120: THE EFFICACY AND SAFETY OF ZANUBRUTINIB AND DEXAMETHASONE IN SYMPTOMATIC WALDENSTROM MACROGLOBULINNEMIA
por: Liu, A., et al.
Publicado: (2022)

P1165: BETALUTIN® IN PATIENTS WITH RELAPSED/ REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) NOT ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT
por: Illidge, T., et al.
Publicado: (2022)

Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study
por: Hawkes, Eliza A., et al.
Publicado: (2021)

Genotyping on ctDNA Identifies Shifts in Mutation Spectrum Between Newly Diagnosed and Relapse/Refractory DLBCL
por: Liu, Hui, et al.
Publicado: (2020)

Efficacy of BIBF 1120 or BIBF 1120 plus chemotherapy on nasopharyngeal carcinoma in vitro and in vivo
por: Xue, Cong, et al.
Publicado: (2016)

Ice swimming – ‘Ice Mile’ and ‘1 km Ice event’
por: Knechtle, Beat, et al.
Publicado: (2015)

Ibrutinib Plus R-ICE Induces Remission in Blastoid Variant Mantle Cell Lymphoma with CNS Relapse
por: Oh, Timothy S., et al.
Publicado: (2022)

Theoretical Prediction of the Anti-Icing Activity of Two-Dimensional Ice I
por: Liu, Sicheng, et al.
Publicado: (2023)

P1138: FIVE-YEAR EFFICACY AND SAFETY OF TAFASITAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY DLBCL: FINAL RESULTS FROM THE PHASE II L-MIND STUDY
por: Duell, Johannes, et al.
Publicado: (2023)

GOALs in relapsed DLBCL
por: Rösler, Wiebke, et al.
Publicado: (2022)

Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy
por: Rentsch, Vera, et al.
Publicado: (2022)

Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL
por: Torka, Pallawi, et al.
Publicado: (2022)

P1134: BISPECIFIC ANTI-CD20/19 CAR-T – ZAMTOCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY DLBCL – INTERIM ANALYSIS RESULTS OF DALY-II-USA STUDY
por: Shah, Nirav, et al.
Publicado: (2023)

P618: LONG-TERM SAFETY WITH ≥12 MONTHS OF PIRTOBRUTINIB IN RELAPSED/REFRACTORY (R/R) B-CELL MALIGNANCIES
por: Jurczak, Wojciech, et al.
Publicado: (2023)

PB2119: LONG-TERM SURVIVAL PROJECTIONS OF LONCASTUXIMAB TESIRINE-TREATED PATIENTS IN RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
por: Hamadani, M., et al.
Publicado: (2022)

Exotic Spectra and Lattice Vibrations of Ice X Using the DFT Method
por: Jiang, Lu, et al.
Publicado: (2018)

Genetic landscapes and curative effect of CAR T-cell immunotherapy in patients with relapsed or refractory DLBCL
por: Shi, Hui, et al.
Publicado: (2022)

P1152: DEPTH OF METABOLIC RESPONSE AT INTERIM PET AND SURVIVAL OUTCOMES AMONG PATIENTS WITH PRIMARY REFRACTORY OR EARLY RELAPSING DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
por: Bock, Allison, et al.
Publicado: (2023)

Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL
por: Zhang, Jing, et al.
Publicado: (2023)

Experimental Study on the Icing Dielectric Constant for the Capacitive Icing Sensor
por: Zhu, Yongcan, et al.
Publicado: (2018)

Ice
Publicado: (1879)

P1154: EFFICACY OF SUBCUTANEOUS EPCORITAMAB VS AXI-CEL IN R/R DLBCL CAR T-NAIVE AND CAR T-ELIGIBLE PATIENTS: AN INDIRECT COMPARISON
por: Thieblemont, Catherine, et al.
Publicado: (2023)

GenIce: Hydrogen‐Disordered Ice Generator
por: Matsumoto, Masakazu, et al.
Publicado: (2017)

Influence of Anthropometric Characteristics on Ice Swimming Performance—The IISA Ice Mile and Ice Km
por: Knechtle, Beat, et al.
Publicado: (2021)

Observing ice structure of micron-sized vapor-deposited ice with an x-ray free-electron laser
por: Kim, Seonmyeong, et al.
Publicado: (2023)

Vitamin D deficiency rickets – tip of the ice burg
por: Atapattu, Navoda, et al.
Publicado: (2015)

CD24 Contributes to Treatment Effect in ABC-DLBCL Patients with R-CHOP Resistance
por: Qiao, Li-Yan, et al.
Publicado: (2021)

P1178: BRENTUXIMAB VEDOTIN IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL: SAFETY AND EFFICACY RESULTS FROM THE SAFETY RUN-IN PERIOD OF THE PHASE 3 ECHELON-3 STUDY
por: Bartlett, N. L., et al.
Publicado: (2022)

P1162: ZANUBRUTINIB IN OLDER PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): SUBGROUP ANALYSIS OF THE MAGNOLIA STUDY
por: Opat, S., et al.
Publicado: (2022)

P1426: WU-NK-101, AN ALLOGENEIC MEMORY NK CELL, FOR THE TREATMENT OF RELAPSE OR REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML)
por: Muth, J. J., et al.
Publicado: (2022)

Skating on thin ice: pragmatic prescribing for medication refractory schizophrenia
por: Tracy, Derek K., et al.
Publicado: (2015)

Comparative analysis of primary versus relapse/refractory DLBCL identifies shifts in mutation spectrum
por: Greenawalt, Danielle M., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_9iqqtqrj0kfud7t571f3em6lfu